It is worth noting that mutations in any of these three genes may affect their predictive utility in this context, however this rarely occurs in HER2+ cancers (less than 10% harbor mutations in EGFR, ERBB3, or CDKN1B [31]). This evidence concerns the gene EGFR and cancer.